These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9420916)

  • 1. In situ proliferative epithelial lesions of the breast.
    Kamel OW; Kempson RL; Hendrickson MR
    Pathology (Phila); 1992; 1(1):65-102. PubMed ID: 9420916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
    Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
    Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benign proliferative lesions and in situ carcinoma of the breast: new immunohistological findings and their biological implications.
    Böcker W; Bier B; Ludwig A; de Hesselle B; Gerdes J
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():41-9. PubMed ID: 7507748
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinicopathologic analysis of breast lesions associated with multiple papillomas.
    Ali-Fehmi R; Carolin K; Wallis T; Visscher DW
    Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucinous breast lesions: diagnostic challenges.
    Tan PH; Tse GM; Bay BH
    J Clin Pathol; 2008 Jan; 61(1):11-9. PubMed ID: 17873114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Borderline breast lesions: diagnostic challenges and clinical implications.
    Masood S; Rosa M
    Adv Anat Pathol; 2011 May; 18(3):190-8. PubMed ID: 21490436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
    Bofin AM; Lydersen S; Hagmar BM
    Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benign and premalignant breast lesions--clinico-pathological correlation].
    Afek A; Shibi R; Kopolovitz G
    Harefuah; 1997 Nov; 133(9):375-8. PubMed ID: 9418343
    [No Abstract]   [Full Text] [Related]  

  • 9. [Interobserver reproducibility in the pathologic diagnosis of borderline ductal proliferative breast diseases].
    Wei B; Bu H; Zhu CR; Guo LX; Chen HJ; Zhao C; Zhang P; Chen DY; Tang Y; Jiang Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):849-53. PubMed ID: 15573772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative study of ductal breast cancer progression. Morphometric evaluation of phenotypical changes occurring in benign and preinvasive epithelial lesions.
    Mariuzzi GM; Mariuzzi L; Mombello A; Santinelli A; Valli M; Rahal D; Thompson D; Bartels PH
    Pathol Res Pract; 1994 Nov; 190(11):1056-65. PubMed ID: 7746739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diseases of the female breast: clinical pathology].
    Torhorst J
    Ther Umsch; 1993 May; 50(5):307-13. PubMed ID: 8397447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
    Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
    Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ductal carcinoma in situ: introduction of the concept of ductal intraepithelial neoplasia.
    Tavassoli FA
    Mod Pathol; 1998 Feb; 11(2):140-54. PubMed ID: 9504685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?
    Middleton LP; Grant S; Stephens T; Stelling CB; Sneige N; Sahin AA
    Mod Pathol; 2003 Feb; 16(2):120-9. PubMed ID: 12591964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triad of columnar cell alteration, lobular carcinoma in situ, and tubular carcinoma of the breast.
    Sahoo S; Recant WM
    Breast J; 2005; 11(2):140-2. PubMed ID: 15730461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast pathology practice: most common problems in a consultation service.
    Putti TC; Pinder SE; Elston CW; Lee AH; Ellis IO
    Histopathology; 2005 Nov; 47(5):445-57. PubMed ID: 16241992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
    Roger P; Sahla ME; Mäkelä S; Gustafsson JA; Baldet P; Rochefort H
    Cancer Res; 2001 Mar; 61(6):2537-41. PubMed ID: 11289127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Classification of preinvasive breast and carcinoma in situ: doubts, controversies, and proposal for new categorizations].
    Dauplat MM; Penault-Llorca F
    Bull Cancer; 2004 Dec; 91 Suppl 4():S205-10. PubMed ID: 15899609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Definition and development of "borderline" lesions in breast cancer. Atypical hyperplasia and carcinoma "in situ"].
    Contesso G
    J Gynecol Obstet Biol Reprod (Paris); 1980; 9(1):101-2. PubMed ID: 7451846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.